Navigation Links
Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
Date:8/5/2008

MONTREAL, Aug. 5 /PRNewswire-FirstCall/ - ProMetic Life Sciences Inc. (TSX:PLI) ("ProMetic") announces today that it has reached an understanding with a fully integrated, U.S.-based, biotechnology company with respect to the development and global commercialization of several biopharmaceutical products in ProMetic's Protein Technology Division.

In addition to licensing, development and milestone fees as well as on-going royalties on sales of products, the definitive agreements will provide for an initial strategic investment in ProMetic of $7 million at a share price of $0.47. This transaction is anticipated to provide a significant funding commitment towards the development and commercialization of the products, which will contribute to ProMetic's revenue growth as early as 2008.

The definitive agreements will also provide for possible additional investments in ProMetic, which may be triggered by either the biotechnology company or ProMetic, upon fulfillment of certain predetermined conditions. Further, the definitive agreements will provide the biotechnology company to have a right to representation on ProMetic's board of directors.

Definitive agreements regarding the deal, which will be subject to customary closing conditions, including TSX approval, are intended to be negotiated and executed in the following weeks.

The Company will file a short form base shelf prospectus or "shelf registration" with Canadian securities regulators in part to facilitate the completion of this transaction.

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. (http://www.prometic.com) is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand(TM) technology. This technology is used in large-scale purification of biologics and the elimination of pathogen
'/>"/>

SOURCE PROMETIC LIFE SCIENCES INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ProMetic and MacoPharma announce successful completion of P-Capt(R) prion reduction filter clinical studies
2. ProMetic announces scale-up of prion removal resin in plasma product for biopharmaceutical use
3. ProMetic provides business update - Over $35 million worth of business secured in January
4. ProMetic announces signature of definitive license agreement with Kedrion for two hyperimmune products
5. ProMetic reports continued positive data in PBI-1402 phase II trial in chemotherapy-induced anemia
6. ProMetic and Sartorius Stedim Biotech collaborate on technology transfer deals in Asia
7. Prometic to present at the American Chemical Society
8. ProMetic to obtain controlling stake in Pathogen Removal and Diagnostic Technologies Inc.
9. ProMetic presents preclinical data for prostate and pancreatic cancer at the AACR Meeting
10. Prometic provides information for its Annual and Special Meeting of Shareholders
11. ProMetic announces Octapharma publication of PRDTS prion removal resin in Octaplas(R) manufacturing process at 30th International Congress of the International Society for Blood Transfusion meeting in Macao SAR, China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... -- Scientists, including University of Oregon chemist Geraldine ... scaffolds of self-assembling, synthetic proteins called peptoid nanosheets ... The accomplishment -- detailed this week in a ... Proceedings of the National Academy of Sciences ... design of the two-dimensional peptoid nanosheets that can ...
(Date:9/2/2014)... September 02, 2014 Myriant Corporation, ... signage of a distribution agreement with Azelis Group, ... distributing Myriant’s bio-succinic acid in the Nordics, Benelux, ... targeting customers in the industrial and base chemicals ... Azelis offers a far-reaching chemical portfolio with extensive ...
(Date:9/2/2014)... 2, 2014  Synthetic Biologics, Inc. (NYSE MKT: ... drug candidates targeting specific pathogens that cause serious ... its final preclinical toxicology study of SYN-004. Per ... bridging study was required to move the Company,s ... the devastating effects of Clostridium difficile (C. ...
(Date:9/2/2014)... The inventors of tinAway, a novel treatment ... seeking support for development costs through a crowdfunding campaign. ... ), was launched on September 1, 2014. , tinAway ... is based on ten years of neuroscience research. ... software engineers, Dr. Ian Dixon and Mr. Tony Burgess, ...
Breaking Biology Technology:UO-Berkeley Lab unveil new nano-sized synthetic scaffolding technique 2Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 2tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 3tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 4tinAway Pty. Ltd. launch a crowdfunding campaign to fund a clinical trial of tinAway, a new potential cure for chronic tinnitus 5
... System Flexibility & Efficiency, MELVILLE, N.Y., ... ) today announced the launch of NIS-Elements ... confocal and widefield,imaging in a single unifying ... microscopy software enables full integration of confocal,specific ...
... Edwards Lifesciences,Corporation (NYSE: EW ), a global leader ... to announce its operating,results for the quarter ended December ... 2008 and will host a conference call at 5:00 ... participate in the conference call, dial (877) 407-8037 or ...
... Cynosure, Inc.,(Nasdaq: CYNO ), a leading ... aesthetic treatment systems, today announced that the company,will ... call on Tuesday,February 12, 2008 at 9:00 a.m. ... Executive Officer Michael Davin and,Executive Vice President and ...
Cached Biology Technology:Nikon Instruments' New NIS-Elements C Delivers Comprehensive Confocal and Widefield Imaging Capabilities in Single Unifying Software Platform 2Edwards Lifesciences to Host Earnings Conference Call on February 5, 2008 2Cynosure to Announce Fourth-Quarter and Full Year 2007 Financial Results on February 12 2
(Date:9/2/2014)... digital distribution of media will have lower carbon ... when file sizes are large. , That,s the ... Journal of Industrial Ecology that looked at ... as PlayStation3. Researchers found that Blu-ray Discs delivered ... than game files downloaded over broadband Internet. For ...
(Date:9/2/2014)... a new study that could ultimately lead to many ... Scripps Research Institute (TSRI) have adapted a chemical approach ... molecules that can treat a form of muscular dystrophy. ... and a disease-causing defect as a catalyst to synthesize ... Matthew Disney.,"Because the treatment is synthesized only in diseased ...
(Date:9/2/2014)... with the participation of the University of Granada has ... place in the Iberian Peninsula around the mid Holocene ... dust coming from the Sahara increased. The data came ... Alpine lake in Sierra Nevada (Granada) , This study, ... based on the sedimentation of atmospheric dust from the ...
Breaking Biology News(10 mins):Scripps Florida scientists make diseased cells synthesize their own drug 2Scientists obtain new data on the weather 10,000 years ago from sediments of a lake in Sierra Nevada 2
... year history of variation in a gene found in plants ... of California, San Diego have found new evidence to support ... , Their study, published this week in an early online ... Sciences, offers new support for the idea that the loss ...
... darkness throws a molecular switch in mammals that shifts the ... state of torpor in mice, a research team led by ... reports in the Jan. 19 edition of Nature. ... hibernation, researchers note that the pivotal metabolic signal that emerged ...
... found in nearly 5 percent of pneumonia patients in ... from the Centers for Disease Control and Prevention report ... Infectious Diseases , "Our preliminary data suggests that human ... among young children," says Alicia Fry, one of the ...
Cached Biology News:UCSD biologists find new evidence for one-way evolution 2Darkness unveils vital metabolic fuel switch between sugar and fat 2Darkness unveils vital metabolic fuel switch between sugar and fat 3Bocavirus infection may be associated with pneumonia in Thailand, especially in children 2